Volume 8, Supplement 1 (Jul/Aug 2017)

Continuing Education Information

Letter From the Guest Editors

Take a Deep Breath: More Treatment Options for Non–Small Cell Lung Cancer

Diagnosis of Lung Cancer

Over the past 10 years, there have been significant advances in the diagnosis of lung cancer. Screening of high-risk patients with computed tomography scans and genomic biomarkers aid in the diagnosis of lung cancer patients at earlier s...

Fundamentals of Lung Cancer Staging

Lung cancer is the leading cause of cancer-related mortality in the United States and the world. The treatment of non–small cell lung cancer (NSCLC) is dependent on adequate staging of disease at diagnosis. Computed tomography (CT) and p...

Predictive and Prognostic Biomarkers and Related Therapies in Non–Small Cell Lung Cancer

Non–small cell lung cancer (NSCLC) is the leading form of lung carcinoma in the United States. Systemic chemotherapy has remained the mainstay of treatment; however, advances in the identification of driver mutations have allowed the dev...

Supportive Care and Management of Treatment-Emergent Adverse Events With Targeted Therapy in Non–Small Cell Lung Cancer

This article provides a summary of current approaches to the management of adverse effects from targeted therapies for non–small cell lung cancer (NSCLC). Agents included in this section are categorized as epidermal growth factor recepto...

Emerging Biomarkers in Non–Small Cell Lung Cancer

Since the identification of epidermal growth factor receptor (EGFR) mutations in a subset of non–small cell lung cancers and the concomitant success of front-line EGFR inhibitors in treating cancers with these mutations, interest in iden...

Immunotherapy Mechanisms of Action in Non–Small Cell Lung Cancer

Immunotherapy is now a mainstay of therapy for several different types of malignancies. Non–small cell lung cancer (NSCLC) has been one of the first solid tumors to show promising clinical trial results in the use of immunotherapy, speci...

Unleashing the Immune System With Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Clinical Review of Adverse Events

Immunotherapy checkpoint inhibitors have dramatically changed our management of metastatic non–small cell lung cancer (NSCLC). Efficacy data have supported immune checkpoint inhibitors as potential first-line options as monotherapy or in...

Emerging Therapies in Non–Small Cell Lung Cancer: Clinical Trials With Novel Agents

Non–small cell lung cancer (NSCLC) continues to be the leader in cancer-related deaths in the United States. Although local therapies such as surgery and special types of radiation appear to deliver the best chance for cure or remission...

Resources for Patients With Non–Small Cell Lung Cancer and Their Caregivers and Providers

Appendix

Priming the Pump Task Force